Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Unknown 2Completed 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Recurrence 2Leukemia 2Carcinoma, Renal Cell 2Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Neoplasm, Residual 1Melanoma 1Kidney Neoplasms 1Graft vs Host Disease 1

Interventions

Cytarabine 35Cyclophosphamide 26Etoposide 18Radiotherapy 16Daunorubicin 16Busulfan 15Peripheral Blood Stem Cell Transplantation 14Methotrexate 14Idarubicin 14Mercaptopurine 12Dexamethasone 12Vincristine 11Thioguanine 9Mitoxantrone 9Doxorubicin 8Asparaginase 8Antilymphocyte Serum 8pegaspargase 7fludarabine phosphate 7Prednisolone 7Polymerase Chain Reaction 7Filgrastim 7Cyclosporine 7Prednisone 6Mycophenolic Acid 5Melphalan 5Leucovorin 5Gene Expression Profiling 5Vindesine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Leukemia × Interferon alpha-2 × Clear all
NCT02185261 2018-06-07

Interferon α for the Therapy of Minimal Residual Disease

Peking University People's Hospital

Phase NA Unknown
81 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia, Recurrence, Neoplasm, Residual

NCT02568241 2016-09-29

IDPR-HSCT

Peking University People's Hospital

Phase 1/2 Unknown
42 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡